In June 2017, CVS compliance staff recommended blocking controlled-substance prescriptions from a Texas doctor named Howard Diamond. According to the Justice Department, a CVS medical director directed that dispensing remain permitted. Diamond had already been escalated for internal review 13 times since 2014.
The warning had reached the people responsible for reviewing it. A recommendation had been made. What happened to the concern when that recommendation was overridden?
That question gives substance to the October 13 settlement, under which CVS agreed to pay $315 million to resolve Controlled Substances Act and False Claims Act allegations. The settlement does not establish liability.
The case raises two practical questions. Does escalation resolve a concern? And does the organization give employees enough time to investigate without putting their performance at a disadvantage?
A Recommendation Was Overridden
DOJ’s complaint, paragraphs 218–235, describes repeated warnings about Diamond. It alleges that dispensing continued after the medical director rejected the blocking recommendation, until weeks after Diamond’s indictment.
The useful distinction is between receiving a warning and resolving it. A report can move through every required channel without the underlying problem being addressed.
An override is not inherently improper. A reviewer might have information that changes the assessment. But an organization needs to be able to explain the decision: what concern was raised, what evidence answered it, and why continued activity was appropriate.
Without that explanation, a completed review tells us that someone considered the matter. It does not tell us that the concern was resolved.
Investigation Competed With Rewarded Work
DOJ also alleged that CVS tied favorable reviews and bonuses to ordinary prescription volume. Controlled substances were nominally excluded from that metric after 2012. The alleged pressure was indirect: investigating those prescriptions consumed time needed to meet other targets. The complaint separately alleges speed measures that included controlled substances and incentives tied to customer satisfaction. See paragraphs 136–149.
Consider a hypothetical pharmacist with a daily target for ordinary prescriptions. An opioid prescription raises concerns that require a lengthy call to the prescriber and additional review. The pharmacist spends 30 minutes investigating, but the daily target remains unchanged.
That pharmacist has done necessary work. Yet the performance measure can make the day look less productive.
Rushing the investigation creates no direct bonus for dispensing an opioid. It frees time for the work that counts toward the target. The incentive lies in the opportunity cost of careful review.
This does not establish that a particular pharmacist skipped a particular investigation because of compensation. It explains how a performance system can discourage conduct that the organization formally requires.
The Record Does Not Establish a Failure Rate
The complaint gives seven named prescriber examples. It does not establish the proportion of flagged prescribers whose reviews were mishandled.
CVS disputed DOJ’s account. In its December 2024 response, it said its program had blocked more than 1,250 practitioners, including nearly 600 the government continues to license, and criticized the government’s standards as shifting.
That figure does not supply the missing denominator. It counts practitioners blocked, rather than everyone flagged or reviewed. It cannot tell us how often concerns were adequately resolved.
The examples support examining specific alleged failures. They do not justify saying that CVS never acted on warnings or that its entire program was ineffective.
